Want to see BBNX full AI Analyst Report?
BBNX Stock Chart & Stats
$19.07
$0.14(0.88%)
At close: 4:00 PM EDT
$19.07
$0.14(0.88%)
Day’s Range― - ―
52-Week Range$8.80 - $32.71
Previous Close$15.99
Volume845.79K
Average Volume (3M)1.30M
Market Cap
$951.07M
Enterprise Value$523.95M
Total Cash (Recent Filing)$180.49M
Total Debt (Recent Filing)$6.51M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Oct 27, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding53,946,213
10 Day Avg. Volume1,083,062
30 Day Avg. Volume1,303,970
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)4.29
Price to Sales (P/S)12.32
P/FCF Ratio-21.97
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue4.40
Enterprise Value/Gross Profit7.55
Enterprise Value/Ebitda-7.34
Forecast
1Y Price Target
$24.17Price Target Upside26.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-2.02
Revenue Forecast (FY)$126.68M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And Improving MarginsRevenue has scaled from approximately $0.2 million in 2022 to $119.0 million on a trailing-twelve-month basis, while gross margin has improved to about 57%. This combination indicates growing product traction and better unit economics as the commercial base expands.
Mint Expands The Product PlatformFDA clearance for Mint adds a new patch-pump product with CGM integration and smartphone control to the company’s platform. Planned pharmacy distribution and substantial 2027 production capacity could broaden adoption and create an additional recurring consumables opportunity.
Recurring Pharmacy Revenue And RetentionThe pharmacy channel can deepen the company’s recurring revenue model because ongoing system use requires continuing supplies. High retention and high-margin pharmacy revenue support greater customer lifetime value, improve revenue visibility, and make growth less dependent on new device sales alone.
Bears Say
Large Losses And Sustained Cash BurnThe company remains materially unprofitable despite strong revenue growth, with large net losses and negative operating and free cash flow. Continued cash consumption reduces the durability of internal funding and leaves execution dependent on existing liquidity or additional external capital.
Operating Expenses Exceed RevenueOperating expenses exceeding quarterly revenue show that the current cost structure has not yet reached operating leverage. Continued investment in sales and research may support expansion, but it also delays break-even and could keep losses elevated if revenue growth moderates.
Active FDA Remediation RiskThe unresolved FDA warning letter remains a structural execution and regulatory risk while remediation is ongoing. Although management reports substantial revisions to complaints handling and post-market surveillance, continued agency scrutiny could consume resources or delay progress on commercialization.
Beta Bionics, Inc. News
BBNX FAQ
What was Beta Bionics, Inc.’s price range in the past 12 months?
Beta Bionics, Inc. lowest stock price was $8.80 and its highest was $32.71 in the past 12 months.
What is Beta Bionics, Inc.’s market cap?
Beta Bionics, Inc.’s market cap is $951.07M.
When is Beta Bionics, Inc.’s upcoming earnings report date?
Beta Bionics, Inc.’s upcoming earnings report date is Oct 27, 2026 which is in 15 days.
How were Beta Bionics, Inc.’s earnings last quarter?
Beta Bionics, Inc. released its earnings results on Jul 29, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.581 by $0.051.
Is Beta Bionics, Inc. overvalued?
According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued.
Does Beta Bionics, Inc. pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
What is Beta Bionics, Inc.’s EPS estimate?
Beta Bionics, Inc.’s EPS estimate is -0.52.
How many shares outstanding does Beta Bionics, Inc. have?
Beta Bionics, Inc. has 53,946,213 shares outstanding.
What happened to Beta Bionics, Inc.’s price movement after its last earnings report?
Beta Bionics, Inc. reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.581. Following the earnings report the stock price went down -5.933%.
Which hedge fund is a major shareholder of Beta Bionics, Inc.?
Currently, no hedge funds are holding shares in BBNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beta Bionics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.17 (26.75% Upside)
$24.17 (26.75% Upside)
Blogger Sentiment
Neutral
BBNX Sentiment 57%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $716.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.69%
12-Months-Change
Fundamentals
Return on Equity
-26.30%
Trailing 12-Months
Asset Growth
-11.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
BBNX Company Deck
BBNX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call emphasized strong commercial momentum (38% YoY revenue growth), meaningful year‑over‑year margin improvement, a healthy cash position (~$225M), and tangible progress across the innovation pipeline (Mint manufacturing readiness, Type 2 pivotal trial alignment, bihormonal iteration plan). Offsetting factors include elevated operating expenses (37% YoY), Q2 operating expenses exceeding revenue, ongoing FDA remediation work, some near‑term revenue volatility from pharmacy stocking dynamics, and timing/clearance risks for new products. Taken together, the positives around growth, margin expansion, capital runway, and concrete product progress modestly outweigh the near‑term cost and regulatory risks.View all BBNX earnings summariesBBNX Stock 12 Month Forecast
Average Price Target
$24.17
▲(26.75% Upside)
Technical Analysis
Ownership Overview
2.17% Insiders
18.42% Mutual Funds
49.02% Other Institutional Investors
20.87% Public Companies and
Individual Investors